 The FDA has amended OraSure Technologies Incs NASDAQ: OSUR Emergency Use Authorization EUA for its InteliSwab COVID-19 rapid tests to only require one test for symptoms of COVID-19. Related Link: OraSure Wins 109M Contract To Increase COVID-19 Test Manufacturing Capacity. 